[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$ucbjf](/topic/$ucbjf)

### Top Social Posts

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"Needhamthe PT on $STOK to $XX from $XX and reiterated at a Buy rating after STOK presented new zorevuneren OLE data in Dravet Syndrome (DS) at the 54th Child Neurology Society (CNS) annual meeting yesterday. $BIIB $JAZZ UCBJY UCBJF Needham said in its note: The new data showed 1) patients treated with zorevunersen had continued improvements in clinical outcomes through X years and 2) an analysis of patients in the OLE who received a similar dosing regimen as the ongoing Ph3 trial continued to show improvements in the Vineland-3 (cognition & behavior) at X years vs. a DS natural history study."  
[X Link](https://x.com/Quantumup1/status/1976615201718903033) [@Quantumup1](/creator/x/Quantumup1) 2025-10-10T11:46Z 3850 followers, 1797 engagements


"BTIG $STOK's PT to $XX from $XX reiterated at a Buy and said that the 36-month data for Zorevunersen (STK-001) seems to bury any remaining questions. $UCBJY $UCBJF $JAZZ $BIIB $ACAD $DNLI BTIG said in its note:"  
[X Link](https://x.com/Quantumup1/status/1957523671742050745) [@Quantumup1](/creator/x/Quantumup1) 2025-08-18T19:23Z 3846 followers, 4067 engagements